Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity.

× No keyword cloud information.

39 in total

1. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.

Authors: Elaine M Sloand; J Joseph Melenhorst; Zachary C G Tucker; Loretta Pfannes; Jason M Brenchley; Agnes Yong; Valeria Visconte; Colin Wu; Emma Gostick; Phillip Scheinberg; Matthew J Olnes; Daniel C Douek; David A Price; A John Barrett; Neal S Young
Journal: Blood Date: 2010-11-19 Impact factor: 22.113

2. WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies.

Authors: Zheyu Li; Yoshihiro Oka; Akihiro Tsuboi; Tomoki Masuda; Naoko Tatsumi; Manabu Kawakami; Tatsuya Fujioka; Nao Sakaguchi; Hiroko Nakajima; Fumihiro Fujiki; Keiko Udaka; Yusuke Oji; Ichiro Kawase; Haruo Sugiyama
Journal: Int J Hematol Date: 2005-12 Impact factor: 2.490

3. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.

Authors: David Avigan; Parameswaran Hari; Minoo Battiwalla; Michael R Bishop; Sergio A Giralt; Nancy M Hardy; Nicolaus Kröger; Alan S Wayne; Katharine C Hsu
Journal: Biol Blood Marrow Transplant Date: 2013-09-07 Impact factor: 5.742

4. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

Authors: Katayoun Rezvani; Agnes S M Yong; Stephan Mielke; Bipin N Savani; Laura Musse; Jeanine Superata; Behnam Jafarpour; Carol Boss; A John Barrett
Journal: Blood Date: 2007-09-17 Impact factor: 22.113

Review 5. Immunotherapy for myeloid leukemias: current status and future directions.

Authors: K el-Shami; B D Smith
Journal: Leukemia Date: 2008-06-19 Impact factor: 11.528

Review 6. Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.

Authors: Raya Mawad; Jack M Lionberger; John M Pagel
Journal: Curr Hematol Malig Rep Date: 2013-06 Impact factor: 3.952

Review 7. Immunotherapy of childhood cancer: from biologic understanding to clinical application.

Authors: Alan S Wayne; Christian M Capitini; Crystal L Mackall
Journal: Curr Opin Pediatr Date: 2010-02 Impact factor: 2.856

8. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.

Authors: Jochen Greiner; Anita Schmitt; Krzysztof Giannopoulos; Markus T Rojewski; Marlies Götz; Isabel Funk; Mark Ringhoffer; Donald Bunjes; Susanne Hofmann; Gerd Ritter; Hartmut Döhner; Michael Schmitt
Journal: Haematologica Date: 2010-01-15 Impact factor: 9.941

9. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Authors: C Berlin; D J Kowalewski; H Schuster; N Mirza; S Walz; M Handel; B Schmid-Horch; H R Salih; L Kanz; H-G Rammensee; S Stevanović; J S Stickel
Journal: Leukemia Date: 2014-08-05 Impact factor: 11.528

10. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.

Authors: Katayoun Rezvani; Agnes S M Yong; Abdul Tawab; Behnam Jafarpour; Rhoda Eniafe; Stephan Mielke; Bipin N Savani; Keyvan Keyvanfar; Yixin Li; Roger Kurlander; A John Barrett
Journal: Blood Date: 2008-11-06 Impact factor: 22.113